Chapter 14. Pharmacologic Treatment of Symptomatic Hypertrophic Cardiomyopathy

  1. Barry J. Maron MD
  1. Mark V. Sherrid MD and
  2. Ivan Barac MD

Published Online: 25 OCT 2007

DOI: 10.1002/9780470987469.ch14

Diagnosis and Management of Hypertrophic Cardiomyopathy

Diagnosis and Management of Hypertrophic Cardiomyopathy

How to Cite

Sherrid, M. V. and Barac, I. (2004) Pharmacologic Treatment of Symptomatic Hypertrophic Cardiomyopathy, in Diagnosis and Management of Hypertrophic Cardiomyopathy (ed B. J. Maron), Blackwell Publishing, Malden, Massachusetts, USA. doi: 10.1002/9780470987469.ch14

Editor Information

  1. Director, The Hypertrophic Cardiomyopathy Center, Minneapolis Heart Institute Foundation, Minneapolis, Minnesota

Publication History

  1. Published Online: 25 OCT 2007
  2. Published Print: 27 FEB 2004

ISBN Information

Print ISBN: 9781405117326

Online ISBN: 9780470987469

SEARCH

Keywords:

  • symptomatic hypertrophic cardiomyopathy;
  • myofiber disarray;
  • perivascular fibrosis;
  • nonatherosclerotic;
  • intramural coronary

Summary

This chapter contains sections titled:

  • Pathophysiology of heart failure symptoms

  • Pharmacologic treatment in the absence of obstruction

  • Significance of outflow obstruction

  • Mechanism of outflow obstruction

  • Pharmacologic treatment of obstruction

  • Mechanism of benefit of negative inotropes

  • Significance of provocable gradients

  • General drug strategies

  • Midcavity obstruction

  • Treatment of coexistent systemic hypertension

  • Treatment of end-stage HCM

  • Prevention of hypertrophy and fibrosis